

A R&D based
Global Biopharmaceutical Company



April. 2017

 Company



 Product Lineup

 Globalization

**A R&D Based Global
Biopharmaceutical
Company**

Successfully developed
the fourth Botulinum
toxin type A product in
the world and Hyaluronic
acid filler
Advancing to more than
60 countries


**Frontier of Korea
Bio Pharmaceutical
Industry**

The frontier of Korea
biopharmaceutical
Industry thanks to
top-tier Biotechnologists,
and to its state-of-the
-art operations and
production facilities


**Value Creation
for Happy &
Healthy life**

Commitment to
providing the best
products through
best technology and
manpower
Continuing extensive
R&D Investment to
evolve into a true
global biotech leader

Core Competitiveness of Company




Territory	Offices
-----------	---------



Recent 5 Years Results

—●— Sales ■ Operating Income

(Unit: 100mn KRW)



Operating
Income

47%

43%

66%

58%

56%

Business Highlights

Highlights

Obtained marketing approval from MFDS for Coretox® 100U


Obtained marketing approval in Mexico for Neuronox® 50U, 100U, 200U

Obtained marketing approval for Neuramis® Series in Russia

Received KGMP approval for Medytox Plant (Osong) and export product approval for Neuronox® 100U

The first year that sales exceed KRW 100bn

 Company



 Product Lineup

 Globalization

biotechnology

Core Capabilities

Product Development

R&D Center

A R&D center for research and development on new biopharmaceutical products will be completed in 2017

Core Capabilities

Design of Gwanggyo R&D Center





A New facility based on EU/cGMP standards enables Medytox to penetrate in US and European countries

Features of Plant

Current Progress

m²

Production Line for Botulinum Toxin Injectable
& R&D Center

III

The facility for botulinum toxin was completed and obtained KGMP approval. The facility for HA filler is being constructed for global expansion


Features of Plant

Design of Plant

m²



Medytox in Sep 2013 licensed its next-generation botulinum toxin product to Allergan, with one of the largest-ever milestone payments for a Korean pharmaceutical player.





Company



Product Lineup



Globalization

Neuronox® is a representative botulinum toxin type A product of Medytox that is being exported to about 60 countries. Neuronox® ranks No.1 in market share in Korea and has gained significant market share in many countries.

Sale of over 6 million Vials

Proven Efficacy & Safety

Proved efficacy and safety in clinical studies, with results published in distinguished academic Journal such as Dermatologic Surgery.

Global Product

Global Product, Neuronox® has been sold in over 60 countries, since its first launch in 2004. Neuronox® is being sold worldwide (Registered in 29 countries, Registration in progress in 30 additional countries)

Various Choices

Neuronox® line up is consisted of 50, 100, 150 and 200 units, offering various choices according to the application. Physicians find it easier to use and the patients more economical.

developed and launched in 2014. INNOTOX® is an innovative excluding animal-derived ingredients and human serum albumin

Currently INNOTOX® is being sold in Korea and it is emerging as the product to show our distinguished R&D capabilities.

First Liquid Formulation in the World

Enhanced Safety

**liquid formulation of botulinum
toxin type A**

Exclusive of animal source and Human
Serum Albumin

User friendly

process, which minimizes potential hygiene
problems

Proven Efficacy & Safety

Proved efficacy and safety in clinical study

Accurate Dose

Exact dose for injection
(INNOTOX® 0.1mL = 4unit)



Coretox® is an advanced new botulinum toxin type A product that excludes animal derivatives, HSA and non-toxin proteins from its ingredients. It prevents the immune system from developing antibodies that would eventually wear down the effects of botulinum toxin type A

The New Choice of Heavy and Regular Users

Medytox has obtained Coretox® marketing approval in 2016, which was developed as the 3rd botulinum toxin type A product. Coretox ® will be launched in Korea market in the second half of 2017



Neuramis® is the premium hyaluronic acid dermal filler product developed and launched in 2013. Neuramis® Deep attained CE mark in 2011 and We have also secured our position in dermal filler market by obtaining the marketing authorization of Neuramis® series, a hyaluronic acid filler containing lidocaine

The New Choice of Hyaluronic Acid Dermal Filler

Enhanced Safety

Enhanced safety by using high quality hyaluronic acid registered in FDA and EDQM as raw material and through enhanced purification process and final sterilization process

Long Lasting Efficacy

Enhanced durability of effect by performing crosslinking twice

High Satisfaction

High customer satisfaction by providing natural looking volume after administration.


Easy to Use

Ideal properties developed scientifically, giving rise to even extrusion force
Even and uniform injection to minimize pain and enhance convenience of administration

Rapidly Growing Sales

(Unit: 100mn KRW)

Neuramis® Sales





Company



Product Lineup




Globalization


Since 2006, the domestic botulinum toxin market has been grown constantly(CAGR:10%)
After 2006 launch, the market share has expanded from 8% to 40%

Domestic Market Size

Unit : KRW100mn



Domestic Market Share




In 2015, US & EU made up 75% of the world botulinum toxin market
(US market : 51%, EU market : 24%, Global market CAGR: 12.3%)

Global Market Size

Global Market Status

Global Market Share

Unit : \$millions



2015


2015

Botulinum toxin market is expected to grow from \$3.6bn to \$5.6bn by 2020
 (US market 50.9%, ROW* 25.0% 24.1%)

Global Market Segmentation


Unit : \$millions

■ Aesthetic ■ Therapeutic




Global Market Portion

■ USA ■ EU ■ ROW



\$3.38bn



\$5.06bn

Registered in 34 countries

ASIA

AZERBAIJAN	GEORGIA	HONG KONG	INDIA	IRAN
KAZAKHSTAN	KOREA	KYRGYZSTAN	LEBANON	
MYANMAR	MONGOLIA	PHILIPPINES	SYRIA	THAILAND
UZBEKISTAN	VIETNNAM			

EUROPE


UKRAINE ESTONIA SPAIN BELARUS

AMERICA

BOLIVIA	BRAZIL	CHILE	COLUMBIA	COSTARICA
DOMINICA REP	EQUADOR	EL SALVADOR	GUATEMALA	
MEXICO	NICARAGUA	PANAMA	PRAGUAY	PERU

* Red : Neuronox® & Neuramis®, Black: Neuronox®, Blue: Neuramis®

Successful direct penetration in EM markets and experience from partnership with Allergan will enable Medytox to go actively to developed markets



	Present	Mid term	Long term
Neuronox®	Neuronox® is selling over 60 countries through local agents	Direct penetration In Asia markets through JV	Penetration in EU and US markets
Liquid solution of botulinum toxin A (INNOTOX®)	Launched INNOTOX® 25U in Korea(Jun, 2014) Launch INNOTOX® 50U in Korea(Jun, 2015)	Marketing approval and launch by Allergan in EU and US markets	Capturing significant market share
Coretox®	Clinical study finished in Korea. Obtain marketing approval Q2 in 2016	Launch Coretox® in overseas markets	Penetration in EU and US markets
Neuramis® Series	Rapidly growing sales in EM market Neuramis® series containing lidocaine obtained approval in Korea(March, 2015)	Penetration in EU market	Penetration in US market

Global Research-based Biopharmaceutical Company